MEI Pharma - MEIP Stock Forecast, Price & News

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

MEI Pharma Stock Performance

MEI Pharma stock opened at $0.53 on Tuesday. The firm's 50 day moving average price is $0.55 and its two-hundred day moving average price is $0.99. MEI Pharma has a twelve month low of $0.41 and a twelve month high of $3.55.

MEI Pharma (NASDAQ:MEIP - Get Rating) last announced its quarterly earnings data on Monday, May 23rd. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.17). The company had revenue of $9.69 million during the quarter, compared to analysts' expectations of $6.25 million. MEI Pharma had a negative net margin of 62.40% and a negative return on equity of 71.32%. As a group, sell-side analysts expect that MEI Pharma will post -0.69 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Alliance Global Partners reduced their price target on MEI Pharma from $9.00 to $5.00 in a research report on Wednesday, April 20th. StockNews.com started coverage on MEI Pharma in a report on Thursday, August 4th. They issued a "hold" rating for the company. Finally, BTIG Research cut their price objective on MEI Pharma to $3.00 and set a "na" rating for the company in a research note on Tuesday, May 24th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $5.13.